Abstract #999926: Effect of Dosing and Titration of Osilodrostat on Efficacy and Safety in Patients With Cushing's Disease (CD): Results From Two Phase III Trials (LINC3 and LINC4)

Two Phase III studies (LINC3 NCT02180217; LINC4 NCT02697734), showed that osilodrostat, a potent oral 11β-hydroxylase inhibitor, is an effective treatment for CD. Reductions in cortisol levels during osilodrostat therapy can lead to hypocortisolism, which may be mitigated by slow dose uptitration. We assessed the effect of the different dose titration schedules in LINC3 and LINC4 on hypocortisolism-related AEs.